RoosterVial™-hUC-20M-CC

cGMP Xeno-Free Human Umbilical Cord-Derived MSCs to Support Allogeneic Cell Therapy Manufacturing

SKU
Product Name
Components
Size
Tissue Type
Quantity
Price
SKU
C04020UC
Product Name
RoosterVial™-hUC-20M-CC
Components

20M XF cGMP cryopreserved cells

Size
1 Vial
Tissue Type

Umbilical Cord

Overview

Overview

RoosterVial™-hUC-CC are off-the-shelf cGMP umbilical-derived human mesenchymal stem/stromal cells, isolated from the perivascular Wharton’s Jelly region of the UC, that provide a consistent, well-characterized starting material supporting use in allogeneic cell therapy manufacturing and extracellular vesicle production.

Starting with donor tissue sourced under Good Tissue Practice (GTP) standards in accordance with 21 CFR Part 1271, each vial contains 20M cells manufactured to a consistent population doubling level. Lot-specific expansion performance testing supports >10-fold expansion within 4-5 days (in prcRoosterNourish™-MSC-CC) and >20 additional population doublings from thaw.

CliniControl hUC-MSCs are compatible with established scalable 2D and 3D protocols to easily manufacture billions of cells or trillions of hMSC-EVs and are designed for immediate use in clinical manufacturing.

Product Information Sheet

Contact us about off-the-shelf Master Cell Bank (MCB) availability to support gene-modified banks and iPSC reprogramming.

RoosterVial-hUC MSCs are manufactured and sold by RoosterBio, INC and supported by licensed technology from Tissue Regeneration Therapeutics Inc. (TRT) core technology and patent family: US 8,790,923; US 8,278,102; US 7,547,546; US 9,611,456; US 9,611,456; US 8,481,311; US 9,611,456.

Product Features

  • 20M cryopreserved xeno-free cells per vial
  • cGMP-manufactured from normal human umbilical cord donor tissue sourced under GTP standards (listed below)
  • FDA Type II Master File in place to streamline regulatory submission
  • Release testing includes: cell count, viability, and flow cytometry for MSC surface marker expression (CD90 and CD166) and negative controls (CD34 and CD45)
  • Safety testing includes: sterility, endotoxin, mycoplasma, and in vitro adventitious agents*
  • Characterization testing includes: G-band karyotyping and population doubling level (PDL), immunomodulatory potential (IDO enzymatic activity), cytokine secretion profile (bFGF, HGF, IL-8, TIMP-1, TIMP-2, and VEGF), and tri-lineage differentiation potential
  • >10-fold expansion in 4 to 5 days when cultured with prcRoosterNourish™-MSC-CC
  • Expansion protocols do not require media exchanges or surface coatings

Intended Use: For Further Manufacturing Use Only. Not intended for diagnostic use or for direct human or veterinary therapeutic use.

CliniControl™ RoosterVial products are manufactured from tissues sourced under GTP standards and at sites that use methods and controls consistent with current Good Manufacturing Practice (cGMP) for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) in accordance with applicable requirements of 21 CFR 1271. Manufacturing sites are ISO 9001–certified. Contact us for region-specific regulatory support.

*Additional viral testing conducted on Master Cell Bank in accordance with FDA’s Draft Guidance for Industry: “Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products”

GMP RoosterVial™-hUC-20M-CC (C04020UC) cultured in RoosterNourish™-MSC-XF expansion profile (left) and hMSC specific cell surface marker expression.
Angiogenic cytokine secretion (right), and immunomodulatory activity (right, IDO activity increase in response to IFNy) of a representative RoosterVial™-hUC-20M-CC (C04020UC).
Trilineage differentiation of a representative RoosterVial™-hUC-20M-CC (C04002UC) lot. Osteogenesis, left; Adipogenesis, middle; Chondrogenesis, right.
Product Documentation & Protocols

Protocols and Information

Login to search Certificates of Analysis and Quality Control Briefs.

Scientific Resources Blog Articles Publications